.jpg)
We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable.
Starting from a deep knowledge of the disease, we have built a technological platform able to “read” the signal of cancer in blood.
We are applying our multi-omics, computational biology and machine learning approach to capture cancer’s signal for high-burden gastrointestinal cancers. Our first blood test, Signal-C®, accurately detect colorectal cancer with a sensitivity of 92% and a specificity of 94%.
The simplicity of the Signal-C® blood-based test and its availability through the Quest Diagnostics network, after FDA approval, will allow increased share of the U.S. population to be screened. As a result, colorectal cancer incidence and mortality can be reduced.
Solving the real needs of clinical practice is essential to our development. For this reason, we involve the scientific community through presentations at the most relevant conferences and congresses.